DGX QUEST DIAGNOSTICS INC Insider Trading

SVP Karthik Kuppusamy sold 8,147 shares of DGX at $200.00 on 2026-06-04 via 10b5-1 plan; retains 13,510 shares post-transaction.

Karthik Kuppusamy, SVP of Clinical Solutions at Quest Diagnostics, executed a scheduled sale of 8,147 shares at $200.00 under a pre-arranged 10b5-1 trading plan, reducing his non-derivative holdings from 21,657 to 13,510 shares. The sale represents a reduction of approximately 37.6% of his pre-transaction holdings, valued at $1,629,400.00. This transaction is mechanical and calendar-driven rather than discretionary; his prior three trades at DGX (two sales on 2025-07-30 and one on 2025-07-31) generated 30-day returns of +8.5%, +8.5%, and +6.8% respectively, with 90-day returns of +6.5%, +6.5%, and +2.8%, indicating his past DGX sales preceded subsequent stock appreciation. At the current price of $197.21, the stock is -7.6% from its 52-week high of $213.50, and DGX trades at a P/E of 21.32 on recent revenue growth of +11.8% year-over-year, suggesting fundamentals remain intact despite the recent pullback.

CEO Davis sold 10,000 DGX shares at $194.14 under pre-arranged 10b5-1 plan

J. E. Davis, who was CEO at the time of this transaction, sold 10,000 shares (132.4K shares remaining post-sale) on 2026-06-01 at $194.14 per share for a total of $1,941,400.00 under a pre-arranged 10b5-1 trading plan, meaning this was a scheduled transaction rather than a discretionary decision. His prior sales at DGX show mixed near-term performance: the most recent prior sale on 2026-03-02 saw 30d returns of -7.0% and 90d returns of -8.3%, while other sales in November 2025 exhibited 30-day declines ranging from -8.2% to -8.8% before recovering to positive 90-day returns. The stock currently trades at $193.16, down -9.5% from its 52-week high of $213.50 and down -7.3% over the trailing 90 days, reflecting broader price weakness in the security since this sale occurred.

EVP Catherine T. Doherty sells 5,558 DGX shares at $206.21 for $1.1M; holds 67.1K post-sale

Doherty, an EVP at Quest Diagnostics, sold 5,558 shares at $206.21 on 2026-03-05, reducing her holdings by 7.6% to 67.1K shares. The sale occurred near the stock's 52-week high of $211.91, with DGX currently trading at $199.21, down 6.0% from that peak but up 5.3% over 30 days and 9.2% over 90 days. Doherty's cross-ticker track record shows 7 prior sells with a 0.00% well-timed rate at the 90-day mark (all prior sells were followed by positive returns), and her 5 prior DGX sales on 2026-02-13 remain unmeasured in outcome; this March sale occurs in a context where her timing accuracy across tickers has been consistently poor. The fundamentals—$2.8B quarterly revenue, +11.8% annual growth, and a reasonable 20.08 P/E—offer no obvious deterioration that would explain the sale as responsive to business concerns.

SVP General Counsel Prevoznik sold 3,878 DGX shares at $206.21 on 2026-03-05; retains 37,557 shares.

Michael Prevoznik, SVP & General Counsel, sold 3,878 shares (9.4% of pre-transaction holdings) at $206.21, reducing his stake from 41,435 to 37,557 shares. The sale occurred at a price $6.00 above the current $199.21 close and within 5% of the 52-week high of $211.91, consistent with timing near recent strength. Across his five prior DGX trades, Prevoznik's timing outcomes have been mixed: two were well-timed at the 90-day mark (negative returns), but three showed positive 90-day returns after the sale, indicating the stock often rose following his exits. His cross-ticker track record shows a 28.57% well-timed sell rate with average 90-day returns of +2.8%, suggesting limited predictive consistency. Quest Diagnostics remains operationally sound with $2.8B quarterly revenue, +11.8% annual growth, and a 20.08 P/E, and the SVP retains a substantial position of 37,557 shares, indicating continuing alignment with the company.

CEO Davis J. E. sold 10,000 DGX shares at $212.52; holdings now 117.2K. Prior DGX sales poorly timed (avg +7.9–8.3% 90d return).

Davis J. E. sold 10,000 shares (7.9% of pre-transaction holdings) at $212.52, reducing his position to 117.2K shares. The sale occurred near the 52-week high of $211.91 and the stock has gained 12.7% over 30 days and 13.2% over 90 days from the transaction date. His prior five trades at DGX have all resulted in positive 90-day returns ranging from +7.5% to +8.3%, indicating poor timing on those sells (the stock rose after each one). His cross-ticker track record shows a 0.00% well-timed rate across 18 prior sells, though with modest average 90-day returns of +6.5%. The company's fundamentals remain solid with quarterly revenue of $2,816,000,000.00 and net income of $245,000,000.00, plus 11.8% annual revenue growth. This sale continues a pattern of poorly-timed exits at this ticker rather than suggesting imminent operational concern.

EVP Doherty sold 26.2K DGX shares for $5.4M across 5 trades on 2026-02-13, reducing holding by 27.8%

Catherine T. Doherty, EVP of Regional Businesses at Quest Diagnostics, executed 5 separate sales totaling 26,165 shares for $5,393,814.70 on 2026-02-13, with a blended average price of $206.15. This represents a substantial 27.8% reduction in her post-transaction holdings from 94,233 to 68,068 shares. The sales occurred near the stock's 52-week high of $209.32 (current price $205.49), in a period of strong momentum (+8.4% over 30 days, +10.5% over 90 days). However, her prior two sales at DGX (both on 2024-11-27) were followed by positive 90-day returns of +8.2% and +7.5%, indicating these earlier exits preceded stock appreciation rather than declines, with a 0% well-timed rate at the 90-day mark at this ticker. The transaction merits tracking to determine whether the elevated price level near the recent high represents a similar pattern or a meaningful shift in the executive's view of valuation.

Quest Diagnostics SVP Plewman sold 5,662 shares at $204.00 for $1.2M; retains 15,381 shares post-sale.

Patrick Plewman, SVP for Diagnostic Services at Quest Diagnostics, sold 5,662 shares at $204.00 on 2026-02-10, reducing his holdings by 26.9% from 21,043 to 15,381 shares. The sale occurred when the stock was trading 1.2% below its 52-week high of $209.32, and within the context of a 30-day gain of +15.0% and 90-day gain of +10.6%, reflecting significant recent upward price momentum. The transaction represents a substantial reduction in direct shareholdings by a senior executive in diagnostic services at a $23.0B company generating $2.8B quarterly revenue, warranting standard monitoring of insider positioning patterns.

CEO Davis sells 55,093 shares at $192.22 avg for $10.6M; retains 120,480 shares post-sale

Davis J. E., CEO and President of Quest Diagnostics, executed 3 separate sales on 2025-11-25 totaling 55,093 shares for $10,589,759.82 at a blended average price of $192.22, reducing his holdings by 31.4%. His cross-ticker track record shows 15 prior sells with a 90-day well-timed rate of 0.00%, and his prior 5 DGX trades at this ticker (all on 2025-04-02) were similarly not well-timed, with subsequent 90-day returns ranging from +5.7% to +6.8%, indicating he sold before gains materialized in prior instances. The current stock price of $189.18 is 1.6% below the 52-week high of $192.35, and the company is trading at a P/E of 21.72 with recent quarterly revenue of $2,816,000,000 and net income of $245,000,000. The transaction occurs after the stock has appreciated 8.2% over 30 days and 4.2% over 90 days, providing context for the timing of this large disposal of equity.

SVP & Chief Commercial Officer Mark E. Delaney sells 7,946 shares of DGX at $187.35; holdings drop to 7,530 shares (-51.3%)

Mark E. Delaney, SVP & Chief Commercial Officer at Quest Diagnostics, sold 7,946 shares at $187.35 for $1,488,683.10, reducing his post-transaction holdings from 15,476 shares to 7,530 shares—a 51.3% reduction in his position. The sale occurred near the 52-week high of $190.58, with the current stock price at $187.61 and the company reporting strong fundamentals including $2.8B quarterly revenue, $245M net income, and 6.7% annual revenue growth. The magnitude of this sale—eliminating half his holdings—is notable for a senior commercial officer, though the transaction price proximity to recent highs provides context for the execution.

SVP & General Counsel Michael E Prevoznik sold 28,463 shares of DGX for $5,326,041.82 near 52-week highs.

Michael E Prevoznik, SVP & General Counsel, executed 2 separate sales totaling 28,463 shares for $5,326,041.82 on 2025-09-23 and 2025-09-24 at an average price of $187.12. This sale reduced his holdings by 42.8%, from 66,580 to 38,117 shares. The transaction occurred when DGX was trading at $185.39, approximately -0.8% from its 52-week high of $186.97, near the upper end of its annual range. His prior 5 sales at DGX over the past year all showed positive 90-day returns (+5.2% to +9.8%), meaning the stock rose after each sale—a pattern indicating his recent sales have been poorly timed relative to subsequent price appreciation. At a blended average price of $187.12, this latest sale was executed slightly above the current price, reflecting recent momentum (+2.8% over 30 days, +4.2% over 90 days).